Comparison of Allogeneic vs Autologous Bone Marrow–Derived Mesenchymal Stem Cells Delivered by Transendocardial Injection in Patients With Ischemic Cardiomyopathy

Short summary

In patients with ischemic cardiomyopathy, transendocardial injection of either allogeneic or autologous mesenchymal stem cells (MSCs) showed comparable low rates of serious adverse events (SAEs) within 30 days and at 1 year, with no significant difference in SAEs between the two groups (33.3% vs. 53.3%, P=.46).

AI-generated from the title and abstract; the full text is not read.